TNXP Tonix Pharmaceuticals Holding Corp.

1.06
-0.1  -9%
Previous Close 1.16
Open 1.15
Price To Book 0.23
Market Cap 2,250,026
Shares 2,122,666
Volume 1,183,235
Short Ratio
Av. Daily Volume 429,709
Stock charts supplied by TradingView

NewsSee all news

  1. Tonix Pharmaceuticals to Present at 12th Annual LD Micro Main Event

    NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) announced today that Company management will present at the 12th Annual LD Micro Main Event being

  2. Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

    NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, today announced that it has regained compliance with the

  3. Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD

    Minutes are Consistent with Guidance Received at FDA Meeting More Than 50 Percent of Enrollment Completed for Phase 3 RECOVERY Trial of Tonmya for PTSD Results from RECOVERY Interim Analysis Expected First Quarter 2020

  4. Tonix Pharmaceuticals to Participate in Benchmark's Annual Discovery 1x1 Conference

    NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will be

  5. Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

    NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that, having successfully closed an

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial halted due to insufficient efficacy - July 27, 2018.
TNX-102 SL (Tonmya)
Post-traumatic stress disorder (PTSD)
Phase 2 data released February 2016 did not meet primary endpoint
TNX-201
Episodic tension-type headache
Phase 3 data September 6, 2016 did not meet primary endpoint - program discontinued. However new Phase 3 program initiated November 21, 2019.
TNX-102 SL
Fibromyalgia
Phase 3 interim analysis 1Q 2020 with top-line data due 2Q 2020.
Tonmya
Post-traumatic stress disorder (PTSD)
In-licensed - noted May 23, 2019.
TNX-1300 (RBP-8000)
Cocaine intoxication
Phase 1 initiation of dosing announced September 4, 2019 with data due by the end of 2019.
TNX-601
PK trial

Latest News

  1. Tonix Pharmaceuticals to Present at 12th Annual LD Micro Main Event

    NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) announced today that Company management will present at the 12th Annual LD Micro Main Event being

  2. Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

    NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, today announced that it has regained compliance with the

  3. Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD

    Minutes are Consistent with Guidance Received at FDA Meeting More Than 50 Percent of Enrollment Completed for Phase 3 RECOVERY Trial of Tonmya for PTSD Results from RECOVERY Interim Analysis Expected First Quarter 2020

  4. Tonix Pharmaceuticals to Participate in Benchmark's Annual Discovery 1x1 Conference

    NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will be

  5. Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

    NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that, having successfully closed an

  6. Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder

    NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has received the official meeting

  7. Tonix Pharmaceuticals Announces Closing of $9.0 Million Public Offering

    NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), clinical-stage biopharmaceutical company, announced today the closing of its previously announced

  8. Tonix Pharmaceuticals Prices $9.0 Million Public Offering

    NEW YORK, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the pricing of an underwritten public

  9. Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

    50% of Enrollment Complete for Phase 3 RECOVERY Trial of Tonmya® for the Treatment of PTSD Results from RECOVERY Interim Analysis Expected First Quarter 2020 Topline Data Expected Second Quarter 2020 Based on

  10. Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting

    Primary Endpoint Will be Mean Change from Baseline in CAPS-5 at Week 12, Instead of Week 4 Results from Added Interim Analysis Expected in First Quarter 2020 Topline Data Expected in Second Quarter 2020 Based on

  11. Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

    NEW YORK, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it will effect a 1-for-10 reverse

  12. Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601

    NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark

  13. Tonix Pharmaceuticals Joins the Alliance for Biosecurity

    NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it has joined the Alliance for

  14. Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD

    NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the European Patent Office's (EPO)

  15. Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg

    NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced Tonix has completed collecting the

  16. Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers

    NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has obtained an exclusive

  17. Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology

    NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the publication of a paper entitled

  18. Tonix Pharmaceuticals to Speak at the 2019 Annual National Association of Veterans' Research and Education Foundations (NAVREF) Conference

    NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will

  19. Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences

    NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) announced today that Company management will present at three upcoming investor conferences.

  20. Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that participants were dosed in a Phase